Merck will gain the exclusive global license for Chinese drugmaker Hansoh’s HS-10535, an experimental oral drug that targets GLP-1 receptors. Read More
https://fortune.com/img-assets/wp-content/uploads/2024/12/GettyImages-1251953326-e1734582075964.jpg?resize=1200,600
2024-12-19 04:24:36
